In vivo studies of a novel hdac inhibitor for treating hemoglobin disorders
Ended Project Grant Awarded Last action
- Award ID
- R42HL136068
- Recipient
-
Cetya Therapeutics, Inc. UEI LJWQMH4FA7P3
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,063,567
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Originally
- Place of performance
- Fort Collins, CO 80526, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$10,288 | |
| Amendment | $550,046 | |
| Amendment | $0 | |
| Amendment | $24,589 | |
| Original award | $499,220 |
Quick answers
Who received award R42HL136068?
R42HL136068 was awarded to Cetya Therapeutics, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on September 1, 2017.
How much is award R42HL136068 worth?
$1,063,567 has been obligated on R42HL136068.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award